# Advancing Postmenopausal Preventive Therapy

> **NCT04103476** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 385 (actual)

## Conditions studied

- Atherosclerosis
- Cognitive Decline

## Interventions

- **COMBINATION_PRODUCT:** Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04103476
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-13
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103476, "Advancing Postmenopausal Preventive Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04103476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*